Cargando…
Cell Based Therapy for Type 1 Diabetes: Should We Take Hyperglycemia Into Account?
Diabetes mellitus is characterized by long standing hyperglycemia leading to numerous life-threatening complications. For type 1 diabetes mellitus, resulting from selective destruction of insulin producing cells by exaggerated immune reaction, the only effective therapy remains exogenous insulin adm...
Autores principales: | Grohová, Anna, Dáňová, Klára, Špíšek, Radek, Palová-Jelínková, Lenka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370671/ https://www.ncbi.nlm.nih.gov/pubmed/30804929 http://dx.doi.org/10.3389/fimmu.2019.00079 |
Ejemplares similares
-
Myeloid - derived suppressor cells in Type 1 diabetes are an expanded population exhibiting diverse T-cell suppressor mechanisms
por: Grohová, Anna, et al.
Publicado: (2020) -
NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment
por: Dáňová, Klára, et al.
Publicado: (2015) -
Optimal Tolerogenic Dendritic Cells in Type 1 Diabetes (T1D) Therapy: What Can We Learn From Non-obese Diabetic (NOD) Mouse Models?
por: Funda, David P., et al.
Publicado: (2019) -
Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications
por: Fucikova, Jitka, et al.
Publicado: (2019) -
Antigen Loading (e.g., Glutamic Acid Decarboxylase 65) of Tolerogenic DCs (tolDCs) Reduces Their Capacity to Prevent Diabetes in the Non-Obese Diabetes (NOD)-Severe Combined Immunodeficiency Model of Adoptive Cotransfer of Diabetes As Well As in NOD Mice
por: Funda, David P., et al.
Publicado: (2018)